Levan is a fructose-based biopolymer with diverse applications in medicinal, pharmaceutical, and food industries. However, despite its extensive biological and pharmacological actions, including antioxidant, anti-inflammatory, and antidiabetic properties, research on its anti-aging potential is limited. This study explored levan's impact on chronological lifespan (CLS) of yeast Saccharomyces cerevisiae for the first time. The results show that levan treatment significantly extended the CLS of wild-type (WT) yeast by preventing the accumulation of oxidative stress markers (reactive oxygen species, malondialdehyde, and protein carbonyl content) and ameliorating apoptotic features such as reduced mitochondrial membrane potential, loss of plasma membrane integrity, and externalization of phosphatidylserine. By day 40 of the CLS, a significant increase in yeast viability of 6.8 % (p < 0.01), 11.9 % (p < 0.01), and 20.8 % (p < 0.01) was observed at 0.25, 0.5, and 1 mg/mL of levan concentrations, respectively, compared to control (0 %). This study's results indicate that levan treatment substantially modulates the expression of genes involved in the TORC1/Sch9 pathway. Moreover, levan treatment significantly extended the CLS of yeast antioxidant-deficient mutant sod2Delta and antiapoptotic gene-deficient mutant pep4Delta. Levan also extended the CLS of signaling pathway gene-deficient mutants such as pkh2Delta, rim15Delta, atg1, and ras2Delta, while not affecting the CLS of tor1Delta and sch9Delta.

• PMID: 38574907
• DOI full text
• PubMed

Reference Type

Journal Article

Authors

Alugoju P, Tencomnao T

Primary Lit For

Additional Lit For

Review For